Greenleaf Trust Takes Position in Insulet Co. (NASDAQ:PODD)

Greenleaf Trust acquired a new position in Insulet Co. (NASDAQ:PODD) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 1,271 shares of the medical instruments supplier’s stock, valued at approximately $276,000.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Gray Wealth Management Inc. acquired a new stake in Insulet in the fourth quarter worth about $234,000. Federated Hermes Inc. lifted its stake in shares of Insulet by 6.2% in the 4th quarter. Federated Hermes Inc. now owns 185,347 shares of the medical instruments supplier’s stock worth $40,217,000 after acquiring an additional 10,883 shares during the period. Avior Wealth Management LLC boosted its holdings in shares of Insulet by 3.6% in the fourth quarter. Avior Wealth Management LLC now owns 2,645 shares of the medical instruments supplier’s stock valued at $574,000 after acquiring an additional 91 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Insulet by 268.8% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 53,974 shares of the medical instruments supplier’s stock valued at $11,711,000 after acquiring an additional 39,337 shares during the period. Finally, Mackenzie Financial Corp raised its holdings in Insulet by 25.5% during the fourth quarter. Mackenzie Financial Corp now owns 7,029 shares of the medical instruments supplier’s stock worth $1,525,000 after purchasing an additional 1,428 shares in the last quarter.

Insider Activity at Insulet

In other news, Director Shacey Petrovic sold 11,609 shares of the company’s stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $162.92, for a total value of $1,891,338.28. Following the sale, the director now directly owns 2,567 shares in the company, valued at approximately $418,215.64. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 0.90% of the stock is currently owned by corporate insiders.

Insulet Stock Performance

PODD stock opened at $167.25 on Thursday. The company has a market capitalization of $11.71 billion, a price-to-earnings ratio of 57.47, a P/E/G ratio of 3.01 and a beta of 0.98. Insulet Co. has a 12 month low of $125.82 and a 12 month high of $335.91. The firm has a 50 day moving average of $172.53 and a two-hundred day moving average of $179.35. The company has a quick ratio of 2.62, a current ratio of 3.51 and a debt-to-equity ratio of 1.86.

Insulet (NASDAQ:PODD) last announced its earnings results on Thursday, February 22nd. The medical instruments supplier reported $1.40 EPS for the quarter, topping the consensus estimate of $0.67 by $0.73. The firm had revenue of $509.80 million for the quarter, compared to the consensus estimate of $461.26 million. Insulet had a net margin of 12.16% and a return on equity of 32.19%. The business’s quarterly revenue was up 37.9% on a year-over-year basis. During the same quarter last year, the firm posted $0.55 EPS. As a group, equities analysts anticipate that Insulet Co. will post 3.08 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have recently commented on the company. Piper Sandler dropped their price objective on Insulet from $250.00 to $230.00 and set an “overweight” rating on the stock in a research note on Friday, February 23rd. Barclays dropped their price target on shares of Insulet from $214.00 to $213.00 and set an “equal weight” rating on the stock in a research report on Monday, February 26th. Stifel Nicolaus lifted their price objective on shares of Insulet from $163.00 to $208.00 and gave the stock a “hold” rating in a research note on Monday, February 5th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Insulet from $190.00 to $225.00 and gave the stock an “overweight” rating in a report on Friday, February 23rd. Four analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $243.21.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.